Roberto Bianco
Impact in
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 105
- HER2/EGFR in Cancer Research 42
- Colorectal Cancer Treatments and Studies 26
- Cancer Treatment and Pharmacology 17
- Cancer Immunotherapy and Biomarkers 11
-
- Lung Cancer Treatments and Mutations 33
- Co-authors
- Fortunato Ciardiello (57 shared papers)Giampaolo Tortora (58 shared papers)Sabino De Placido (49 shared papers)Vincenzo Damiano (26 shared papers)Rosa Caputo (13 shared papers)A R Bianco (18 shared papers)G Pomatico (6 shared papers)Gabriella Fontanini (11 shared papers)
- Journals
- Clinical Cancer Research (14 papers)Insights into Imaging (9 papers)British Journal of Cancer (9 papers)Cancers (8 papers)Oncotarget (7 papers)
- Partner nations
- ItalyUnited StatesBrazil
In The Last Decade
Roberto Bianco
193 papers receiving 8.6k citations
Roberto Bianco's Hit Papers
Peers
Comparison fields: 5 of 134
- Oncology 5.0k
- Pulmonary and Respiratory Medicine 3.4k
- Cancer Research 1.2k
- Molecular Biology 3.7k
- Radiology, Nuclear Medicine and Imaging 898
Countries citing papers authored by Roberto Bianco
This map shows the geographic impact of Roberto Bianco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Bianco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Bianco more than expected).
Fields of papers citing papers by Roberto Bianco
This network shows the impact of papers produced by Roberto Bianco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Bianco. The network helps show where Roberto Bianco may publish in the future.
Co-authors
The 25 scholars most cited alongside Roberto Bianco, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 208 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Hit paper breakdown → | 2000 | 817 |
| 2 | Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Hit paper breakdown → | 2001 | 531 |
| 3 | Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. | 2001 | 465 |
| 4 | 2003 | 357 | |
| 5 | Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. | 2000 | 321 |
| 6 | 1999 | 302 | |
| 7 | 2004 | 285 | |
| 8 | Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. | 1999 | 280 |
| 9 | Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). | 2002 | 205 |
| 10 | 2003 | 158 | |
| 11 | 2005 | 153 | |
| 12 | 2017 | 137 | |
| 13 | Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. | 2003 | 134 |
| 14 | 2019 | 133 | |
| 15 | 2015 | 128 | |
| 16 | 2013 | 125 | |
| 17 | 2008 | 117 | |
| 18 | 2007 | 107 | |
| 19 | Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. | 2000 | 107 |
| 20 | 2006 | 105 |
About Roberto Bianco
Roberto Bianco is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Radiology, Nuclear Medicine and Imaging, having authored 208 papers that have together received 8.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (42 papers), Lung Cancer Treatments and Mutations (33 papers), Colorectal Cancer Treatments and Studies (26 papers), Monoclonal and Polyclonal Antibodies Research (19 papers), Cancer Treatment and Pharmacology (17 papers), PI3K/AKT/mTOR signaling in cancer (17 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). The work is most often cited by research in Oncology (5.0k citations), Pulmonary and Respiratory Medicine (3.4k citations), Cancer Research (1.2k citations), Molecular Biology (3.7k citations) and Radiology, Nuclear Medicine and Imaging (898 citations). Roberto Bianco has collaborated with scholars based in Italy, United States and Brazil. Frequent co-authors include Fortunato Ciardiello, Giampaolo Tortora, Sabino De Placido, Vincenzo Damiano, Rosa Caputo, A R Bianco, G Pomatico, Gabriella Fontanini, Roberta Rosa and Carlos L. Arteaga. Their work appears in journals such as Clinical Cancer Research, Insights into Imaging, British Journal of Cancer, Cancers and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.